Anticancer Properties of Novel Rhenium Pentylcarbanato Compounds against MDA-MB-468(HTB-132) Triple Node Negative Human Breast Cancer Cell Lines

Carl Parson; Valerie Smith; Christopher Krauss; Hirendra N Banerjee; Christopher Reilly; Jeanette A Krause; James M Wachira; Dipak Giri; Angela Winstead; Santosh K Mandal

doi:10.9734/BJPR/2014/4697

Anticancer Properties of Novel Rhenium Pentylcarbanato Compounds against MDA-MB-468(HTB-132) Triple Node Negative Human Breast Cancer Cell Lines

Br J Pharm Res. 2015 Feb 1;4(3):362-367. doi: 10.9734/BJPR/2014/4697.

Authors

Affiliations

¹ Department of Biology and Pharmaceutical Sciences, Elizabeth City State University, University of North Carolina, Elizabeth City, NC, 27909, USA.
² Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, 24061, USA.
³ Department of Chemistry, University of Cincinnati, Cincinnati, OH, 45221, USA.
⁴ Department of Biology, Morgan State University, Baltimore, MD, 21251, USA.
⁵ Department of Chemistry, Morgan State University, Baltimore, MD, 21251, USA.

Abstract

Aim: To study the efficacy of novel rhenium compounds to treat triple node negative breast cancer.

Place and duration: Six (6) novel rhenium pentycarbanato compounds (PC1-6) were synthesized and triple node negative breast cancer cell lines HTB-132 and Balb/c mouse kidney cell lines were treated with each of them for 48 hours. The results were analyzed by a common trypan blue cell death assay system and statistically analyzed.

Place and duration: The compounds were synthesized, analyzed and evaluated at the Department of Chemistryof Morgan State University, Baltimore, Maryland and the Pharmaceutical Sciences Department of Elizabeth City State University campus of the University of North Carolina system.

Methodology: The novel rhenium compounds were synthesized from one-pot reactions of Re₂(CO)₁₀ with the corresponding α-diimine ligands in 1-pentanol.The compounds were characterized spectroscopically. The cell lines were cultured by standard cell culture procedure and treated with each of the six compounds in DMSO for 48 hours with a negative control and a DMSO vehicular control along with a cisplatin positive control.The cytotoxicity was evaluated by standard trypan blue assay and the results were statistically analyzed.

Results: The trypan blueassay reveals that these compounds have significant cytotoxicity against MDA-MB-468 (HTB-132) triple node negative breast cancer cell lines and are less nephrotoxic than cisplatin.

Conclusion: The novel rhenium compounds PC 1-6 can potentially find applications in the treatment of highly malignant triple node negative breast cancer.

Keywords: HTB-132 breast cancer cells; Rhenium pentylcarbonato compounds; cytotoxicity; trypan blue assay.

Abstract

Grants and funding